Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07009145 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 6, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. Eligible participants who meet the inclusion and exclusion criteria will provide written informed consent and receive QL1706 at 5.0 mg/kg and bevacizumab at 7.5 mg/kg on Day 1 of every 3-week cycle (Q3W), until disease progression or completion of 2 years of treatment. The primary endpoint of this study is objective response rate (ORR). Secondary endpoints include disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), PFS and OS rates at 6, 12, and 24 months, and safety.
Trial Details
NCT Number NCT07009145
Lead Sponsor Qianfoshan Hospital
Collaborators: Linyi Tumour Hospital, Shandong Provincial Hospital, Qingdao Central Hospital
Conditions
(from sponsor)		 Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov